ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1214

Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis

Sangmee Bae1, Srijana Davuluri2, Brian Lee3, Sean Lim4, Daniela Markovic5, Lorinda Chung2, David Fiorentino6 and Christina Charles-Schoeman7, 1UCLA Rheumatology, Los Angeles, CA, 2Stanford University, Stanford, CA, 3Stanford University, Stanford, 4Stanford University, Palo Alto, 5UCLA, Los Angeles, 6Department of Dermatology, Stanford University Medical Center, Stanford, CA, 7UCLA Medical Center, Santa Monica, CA

Meeting: ACR Convergence 2025

Keywords: calcinosis, Myositis, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Calcinosis is a feature seen in systemic sclerosis (SSc) and dermatomyositis (DM) that leads to significant morbidity and poor quality of life. Inflammatory vasculopathy is hypothesized to play a role in dystrophic mineral deposition. Paraoxonase1 (PON1) is a high-density lipoprotein (HDL) associated protein that protects the vascular endothelium from oxidative injury and damage. The current study aims to assess the association of calcinosis PON1 activity in SSc and DM patients.

Methods: Calcinosis is a feature seen in systemic sclerosis (SSc) and dermatomyositis (DM) that leads to significant morbidity and poor quality of life. Inflammatory vasculopathy is hypothesized to play a role in dystrophic mineral deposition. Paraoxonase1 (PON1) is a high-density lipoprotein (HDL) associated protein that protects the vascular endothelium from oxidative injury and damage. The current study aims to assess the association of calcinosis PON1 activity in SSc and DM patients.

Results: Among 258 SSc patients and 652 DM patients, we identified a total of 186(20%) patients who ever had calcinosis. Calcinosis was more common in SSc (39.6%) compared to DM (13%, p< 0.0001). Calcinosis was associated with longer disease duration in both SSc and DM (Table 1). In SSc, patients with calcinosis were more often white and had higher skin scores, while DM patients with calcinosis were significantly younger, had higher sedimentation rate and had higher incidence of anti SAE and NXP2 antibodies compared to DM without calcinosis (Table 1). Clinical manifestations associated with calcinosis in SSc were digital ulcerations, telangiectasias, and acro-osteolysis, while in DM associated factors were skin ulcers and inflammatory arthritis. PON1 paraoxonase activity was significantly lower in SSc patients with calcinosis compared to SSc without calcinosis, and a similar trend was seen within each DM cohort (Figure 1-a). Association between calcinosis and low PON1 was significant when the two DM cohorts were combined (Figure 1-b). Multivariate models adjusting for age, sex and disease duration demonstrated that the association between low paraoxonase and calcinosis was significant in SSc, in DM total (DM1+DM2) and in all 3 cohorts combined (SSc+DM1+DM2) (Table 2). SSc patients overall had a significantly lower paraoxonase activity compared to DM (p=0.0002), and SSc patients with calcinosis had the lowest paraoxonase activity.

Conclusion: In our current work, calcinosis was observed in 40% of SSc and 13% of DM patients. Calcinosis was associated with longer disease duration and ulcerations in both SSc and DM. Impairment in the activity of the PON1 enzyme, which normally protects the vascular endothelium from oxidative injury, was associated with the presence of calcinosis in both DM and SSc patients, suggesting potential involvement in the disease pathogenesis.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Bae: None; S. Davuluri: None; B. Lee: None; S. Lim: None; D. Markovic: None; L. Chung: AbbVie/Abbott, 1, Boehringer-Ingelheim, 1, CRISPR Therpeutics, 2, Cure Ventures, 2, jade, 2, Kyverna, 6, Mediar, 1, 2; D. Fiorentino: None; C. Charles-Schoeman: AbbVie/Abbott, 2, 5, Alexion, 5, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, 5, CSL Behring, 5, Galapagos, 2, Immunovant, 2, Janssen, 5, Octapharma, 2, 5, Pfizer, 2, 5, Priovant, 5, Recludix, 2, Sana Biotechnology, 2.

To cite this abstract in AMA style:

Bae S, Davuluri S, Lee B, Lim S, Markovic D, Chung L, Fiorentino D, Charles-Schoeman C. Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/association-of-paraoxonase1-activity-with-calcinosis-in-patients-with-scleroderma-and-dermatomyositis-an-exploratory-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-paraoxonase1-activity-with-calcinosis-in-patients-with-scleroderma-and-dermatomyositis-an-exploratory-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology